Zomedica Pharma ( (ZOMDF) ) has released its Q3 earnings. Here is a breakdown of the information Zomedica Pharma presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Zomedica Corp. is a Michigan-based animal health company specializing in point-of-care diagnostic and therapeutic products for equine and companion animals, known for its innovative solutions like the PulseVet shock wave system and TRUFORMA diagnostic platform.
In its latest earnings report, Zomedica announced a 16% increase in revenue for the third quarter of 2025, reaching $8.1 million, marking the 19th consecutive quarter of year-over-year revenue growth. The company also reported a strong gross margin of 67% and highlighted its robust liquidity position with $54 million in cash and equivalents.
Key financial highlights include a 51% growth in the Diagnostics segment, driven by the TRUFORMA platform, and a 14% increase in consumable sales. The introduction of a new Development Services segment contributed $0.7 million in revenue, showcasing Zomedica’s strategic expansion into the human health sector. Additionally, international sales grew by 16%, supported by new distribution agreements in the UK, Netherlands, and Canada.
Despite a net loss of $6.1 million, down 9% from the previous year, Zomedica’s operational efficiencies led to a reduction in operating expenses and a 19% decrease in Non-GAAP EBITDA loss. The company remains optimistic about achieving cash flow breakeven and profitability, supported by its strategic initiatives and strong balance sheet.
Looking ahead, Zomedica plans to continue its product expansion and international growth, with upcoming enhancements to its TRUFORMA platform and the launch of the TRUVIEW AI platform, aiming to further solidify its position in the veterinary healthcare market.